Researchers have identified new biomarkers that may predict the success of immunotherapy in metastatic kidney cancer. These biomarkers could help guide treatment decisions, potentially leading to more effective use of immunotherapy and combination therapies. The discovery is part of ongoing research into the mechanisms of immune checkpoint inhibition and its applications in renal cell carcinoma.